January 6, 2026

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation

Key Points

To evaluate the effectiveness of benralizumab in severe eosinophilic asthma in a real-life setting.
Retrospective study involving biologic-naïve adults with severe eosinophilic asthma.
Assessment of outcomes at baseline and week 32 after initiating benralizumab.
Evaluation of peripheral blood eosinophil count, exacerbations, Asthma Control Test scores, and spirometric parameters.
Median peripheral blood eosinophil count decreased significantly.
Median annual exacerbation frequency declined by 67%.
Asthma Control Test scores improved significantly from baseline to week 32.
Mean FEV₁ increased significantly over the 32-week period.

Abstract

Background: Benralizumab, an anti–IL-5 receptor monoclonal antibody, induces near-complete eosinophil depletion and has demonstrated significant clinical benefits in severe eosinophilic asthma (SEA). Real-world data remain essential for evaluating its effectiveness outside controlled trial settings. Objectives: To assess the clinical, laboratory, and functional outcomes of benralizumab over 32 weeks in a real-life cohort of SEA patients in Türkiye, following its recent national approval. Methods: This retrospective study included biologic-naïve adults with SEA who initiated benralizumab between November 2023 and February 2025 and completed at least six consecutive doses. Peripheral blood eosinophil count (PBEC), clinically significant exacerbations (CSE), Asthma Control Test (ACT) scores, and spirometric parameters were evaluated at baseline and week 32. Patients were classified as responders (ACT ≥20 and no CSE) or non-responders. Results: Twenty-four patients (66.7% female; mean age 50.9 ± 13.1 years) were included. Median PBEC decreased from 800 (230–2200) to 0 (0–100) cells/µL (p < 0.001). Median annual CSE frequency declined by 67% (p < 0.001). ACT scores improved from 9 (5–24) to 22 (9–25) (p < 0.001). Mean Forced expiratory volume in one second (FEV₁) increased from 1719 ± 768 mL to 2165 ± 831 mL (p < 0.001), while Forced vital capacity (FVC) showed significant improvement. Forced Expiratory Flow between 25% and 75% of the Forced Vital Capacity (FEF 25–75) exhibited a nonsignificant trend toward increase. Sixteen patients (66.7%) were classified as responders. Responders had higher baseline PBEC, FEV₁, and FEF25–75 values. Benralizumab was well tolerated, with only two mild adverse events observed. Conclusion: Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice.

Mark Helpful

Bookmark

Relay